Daniel Wendling1, Xavier Guillot2, Laure Gossec3, Clément Prati4, Alain Saraux5, Maxime Dougados6. 1. Department of Rheumatology, CHRU de Besançon, University Teaching Hospital, Boulevard Fleming, 25030 Besançon, France; Université de Franche-Comté, 25030 Besançon, France. Electronic address: dwendling@chu-besancon.fr. 2. Department of Rheumatology, CHRU de Besançon, University Teaching Hospital, Boulevard Fleming, 25030 Besançon, France. 3. Sorbonne Universités, UPMC Université Paris 06, Institut Pierre-Louis d'Épidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), 75013 Paris, France; AP-HP, Pitié-Salpêtrière Hospital, Department of Rheumatology, 75013 Paris, France. 4. Department of Rheumatology, CHRU de Besançon, University Teaching Hospital, Boulevard Fleming, 25030 Besançon, France; Université de Franche-Comté, 25030 Besançon, France. 5. Service de rhumatologie, CHU de Brest, 29609 Brest cedex, France. 6. Université Paris Descartes, Service de rhumatologie, Hôpital Cochin, Assistance publique-Hôpitaux de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France; INSERM (U1153): Épidémiologie clinique et biostatistique, PRES Sorbonne Paris-Cité, 109, avenue de France, 75013 Paris, France.
Abstract
INTRODUCTION: No evaluation of factors associated with remission has been performed in early SpA. The aim of the study was to evaluate percentage of patients in remission using and comparing different definitions of remission, and to evaluate factors associated with remission at inclusion in the prospective DESIR cohort, and after 24 months. METHODS: Performance of three definitions (ASAS partial remission [PR], ASDAS-CRP less than 1.3 [ASDAS-R], BASDAI less than 3.6 [BASDAI-R]) were assessed using sensibility, specificity and Youden Index. Data at M0 and M24 were analyzed in uni- and multivariate analysis. RESULTS: Seven hundred and six patients were evaluated at M0 and 577 at M24. At M0, percentage of patients in remission was 4% (PR), 8% (ASDAS), 34% (BASDAI), and at M24: 15%, 24% and 54% respectively, in the whole population and similar in Amor, ESSG and ASAS classified patients. BASDAI less than 3.6 had the best sensitivity, and ASDAS-R the best Youden index when using each of the two other definitions of remission as a gold standard. At M24 in multivariate analysis, remission was associated with less smoking, less analgesics, ASAS clinical arm fulfilling, less NSAIDs (ASDAS-R), low CRP (ASDAS-R), low BMI (BASDAI-R). However, over the two years, this study did not allow to demonstrate a relation between remission and structural progression or morbidity. CONCLUSION: In this population suggestive of early SpA, smoking and CRP appear as major markers of disease activity in early SpA, and associated with absence of remission.
INTRODUCTION: No evaluation of factors associated with remission has been performed in early SpA. The aim of the study was to evaluate percentage of patients in remission using and comparing different definitions of remission, and to evaluate factors associated with remission at inclusion in the prospective DESIR cohort, and after 24 months. METHODS: Performance of three definitions (ASAS partial remission [PR], ASDAS-CRP less than 1.3 [ASDAS-R], BASDAI less than 3.6 [BASDAI-R]) were assessed using sensibility, specificity and Youden Index. Data at M0 and M24 were analyzed in uni- and multivariate analysis. RESULTS: Seven hundred and six patients were evaluated at M0 and 577 at M24. At M0, percentage of patients in remission was 4% (PR), 8% (ASDAS), 34% (BASDAI), and at M24: 15%, 24% and 54% respectively, in the whole population and similar in Amor, ESSG and ASAS classified patients. BASDAI less than 3.6 had the best sensitivity, and ASDAS-R the best Youden index when using each of the two other definitions of remission as a gold standard. At M24 in multivariate analysis, remission was associated with less smoking, less analgesics, ASAS clinical arm fulfilling, less NSAIDs (ASDAS-R), low CRP (ASDAS-R), low BMI (BASDAI-R). However, over the two years, this study did not allow to demonstrate a relation between remission and structural progression or morbidity. CONCLUSION: In this population suggestive of early SpA, smoking and CRP appear as major markers of disease activity in early SpA, and associated with absence of remission.
Authors: Maud Wieczorek; James Martin Gwinnutt; Maxime Ransay-Colle; Suzanne Mm Verstappen; Francis Guillemin; Andra Balanescu; Heike Bischoff-Ferrari; Annelies Boonen; Giulio Cavalli; Savia de Souza; Annette de Thurah; Thomas Ernst Dorner; Rikke Helene Moe; Polina Putrik; Javier Rodríguez-Carrio; Lucía Silva-Fernández; Tanja A Stamm; Karen Walker-Bone; Joep Welling; Mirjana Zlatkovic-Svenda Journal: RMD Open Date: 2022-03
Authors: Laura Pina Vegas; Emilie Sbidian; Daniel Wendling; Philippe Goupille; Salah Ferkal; Philippe Le Corvoisier; Bijan Ghaleh; Alain Luciani; Pascal Claudepierre Journal: Rheumatology (Oxford) Date: 2022-04-11 Impact factor: 7.580